Market Closed -
Other stock markets
|
After market 05:30:00 am | |||
151.2 USD | -0.02% | 150.7 | -0.34% |
21/05 | Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship | MT |
21/05 | J&J: positive trial for Tremfya in ulcerative colitis | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.51% | 36TCr | |
+37.78% | 72TCr | |
+31.50% | 60TCr | |
+19.94% | 33TCr | |
+5.14% | 29TCr | |
+15.98% | 24TCr | |
-4.34% | 21TCr | |
+9.98% | 21TCr | |
+9.32% | 17TCr | |
-0.80% | 16TCr |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167